<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45280">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01951326</url>
  </required_header>
  <id_info>
    <org_study_id>RHB-104-01</org_study_id>
    <nct_id>NCT01951326</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease</brief_title>
  <acronym>MAPUS</acronym>
  <official_title>A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects With Moderately to Severely Active Crohn's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RedHill Biopharma Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RedHill Biopharma Limited</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Canada: Health Canada</authority>
    <authority>Israel: Ministry of Health</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that RHB-104 will have greater efficacy than placebo in
      Crohn's disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess
      the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects with Moderately to
      Severely Active Crohn's Disease.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">October 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Remission at week 26</measure>
    <time_frame>Baseline to week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reduction of the total Crohn's Disease Activity Index (CDAI) score to less than 150</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response at week 26</measure>
    <time_frame>Baseline to week 26</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reduction of CDAI score by a minimum of 100 points</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to remission and response</measure>
    <time_frame>Baseline through week 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time (weeks after randomization) that a subject first records a state of remission or response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission and response</measure>
    <time_frame>Baseline through week 52</time_frame>
    <safety_issue>No</safety_issue>
    <description>The time that a subject is in a state of remission or response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maintenance of remission</measure>
    <time_frame>52 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Remission in a subject from week 26 through week 52.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of subjects in remission</measure>
    <time_frame>52 Weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects who maintained remission</measure>
    <time_frame>Baseline to week 52</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>RHB-104 plasma concentration measurements at different time points</measure>
    <time_frame>Baseline through week 56</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Changes in MAP blood status by polymerase chain reaction (PCR)</measure>
    <time_frame>Baseline through week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in Crohn's Disease Endoscopic Index of Severity (CDEIS)</measure>
    <time_frame>Baseline through week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in Inflammatory Bowel Disease Questionnaire (IBDQ) and Short Form 36 (SF-36)</measure>
    <time_frame>Baseline through Week 52</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Change in inflammatory markers</measure>
    <time_frame>Baseline through Week 52</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of subjects tapered off steroids</measure>
    <time_frame>Baseline through Week 52</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Tissue levels of the active agents of RHB-104 in colon biopsy samples</measure>
    <time_frame>Baseline to Week 26</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Number of subjects with adverse events as a measure of safety and tolerability</measure>
    <time_frame>Baseline through Week 56</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Crohn's Disease</condition>
  <arm_group>
    <arm_group_label>RHB-104</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 RHB-104 capsules administered orally BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5 placebo capsules administered orally BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RHB-104</intervention_name>
    <description>95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine</description>
    <arm_group_label>RHB-104</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5 placebo capsules administered orally BID</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Males and females 18 to 75 years of age

          2. Signed fully informed consent provided as per this protocol

          3. Diagnosis of Crohn's Disease confirmed by endoscopy or radiography and/or histology
             at least 6 months prior to randomization into the study

          4. CD involving the ileum and/or colon

          5. Moderately to severely active CD (Crohn's Disease Activity Index (CDAI) score of ≥
             220 and ≤450) at baseline

          6. Subject must be intolerant or have insufficient response to conventional therapy

          7. Subjects must meet concomitant medication criteria described below:

             Oral 5-acetyl salicylic acid (5-ASA) compounds

               -  If currently being taken, dose must be stable for at least 4 weeks

               -  If discontinued due to lack of response or lack of tolerance, the stop-date must
                  have been at least 4 weeks prior to baseline

             Corticosteroid therapy

               -  If currently being taken, dose must be stable for at least 2 weeks

               -  If discontinued due to lack of a response or lack of tolerance, stop date must
                  have been at least 2 weeks prior to baseline

             Azathioprine or 6-mercaptopurine (6-MP) or methotrexate

               -  If currently being used, dose must be stable for at least 8 weeks

               -  If discontinued due to a lack of response or lack of tolerance, stop date must
                  have been at least 4 weeks prior to baseline

          8. White blood cell count ≥ 3.5x109 at screening

          9. Active Crohn's disease, defined by at least one of the following: C-reactive protein
             &gt; Upper Limit of Normal (ULN) at screening, fecal calprotectin &gt; Upper Limit of
             Normal (ULN) at screening, OR photographic confirmation of the presence of active CD
             within 4 weeks of screening visit.

         10. Subject agrees to use barrier contraceptive methods (i.e. diaphragm, cervical cap,
             contraceptive sponge or condom) with spermicidal foam/gel/cream/suppository, or
             intrauterine device (IUD) throughout the study and for at least 6 weeks after last
             study drug administration, unless subject is post-menopausal or otherwise incapable
             of becoming pregnant by reason of surgery or tubal ligation, or has had a vasectomy.

        Exclusion criteria

          1. Crohn's Disease involvement isolated to the mouth, upper gastrointestinal tract, or
             anus

          2. History of total colectomy with ileorectal anastomosis or a proctocolectomy.

          3. History of fistulizing Crohn's Disease

          4. Subject has postoperative stoma, ostomy, or ileoanal pouch

          5. Subject has short bowel syndrome

          6. Subject is scheduled for surgical bowel resection

          7. Subject has known symptomatic obstructive strictures or bowel perforation in the 6
             months prior to screening

          8. Treatment with anti-Tumor Necrosis Factor (TNF) biologic agents (e.g. monoclonal
             antibody therapies), other agents intended to reduce TNF, or other biological
             therapies &lt; 8 weeks prior to baseline or within 5 half-lives of agent prior to
             baseline, whichever is longer

          9. Previous treatment with rifabutin and/or clofazimine

         10. Oral or parenteral antibiotics in the 4 weeks prior to baseline (topical antibiotics
             are permitted)

         11. Treatment with probiotics (excluding yogurt and yogurt-derived products) in the 4
             weeks prior to screening

         12. Females who have a positive pregnancy test or are lactating
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ira N Kalfus, MD</last_name>
    <role>Study Director</role>
    <affiliation>RedHill Biopharma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Y. Graham, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Medicine/Gastroenterology, Baylor College of Medicine, Houston</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lynn Institute of the Ozarks, 500 S. University #500</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harmony Cole</last_name>
      <phone>501-975-2000</phone>
      <email>hcole@lhsi.net</email>
    </contact>
    <investigator>
      <last_name>Glenn Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Applied Research Center of Arkansas, Inc., 11524 North Rodney Parham, Suite 8</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorrie Brickell, LPN</last_name>
      <phone>501-954-7822</phone>
      <email>lorrie@arcarkansas.com</email>
    </contact>
    <investigator>
      <last_name>Louis Duane Velez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medvin Clinical Research, 15627 Imperial Highway,</name>
      <address>
        <city>La Mirada</city>
        <state>California</state>
        <zip>90638</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Gonzales</last_name>
      <phone>562-479-0330</phone>
      <email>maria@medvinresearch.com</email>
    </contact>
    <investigator>
      <last_name>Richard McGuire, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaiser Pemanente Medical Center GAS, Kaiser Pemanente Medical Center GAS</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tashia Orr</last_name>
      <phone>916-973-5714</phone>
      <email>tashia.orr@Kp.org</email>
    </contact>
    <investigator>
      <last_name>Michael J. Lawson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Digestive Care Associats, Inc., 1000 Laurel St.</name>
      <address>
        <city>San Carlos</city>
        <state>California</state>
        <zip>94070</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MaryAnn Braesesco</last_name>
      <phone>650-596-8800</phone>
      <email>studysite@sbcglobal.net</email>
    </contact>
    <investigator>
      <last_name>Scott Levenson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ventura Clinical Trials, 1746 South Victoria, Suite #230, 220</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alex Martinez</last_name>
      <phone>800-920-0016</phone>
      <email>martineza1504@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Sabine Hazan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Research Center of Connecticut, LLC</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Nikolich, RN</last_name>
      <phone>203-281-5161</phone>
      <email>jNikolich@gastrocenter.org</email>
    </contact>
    <investigator>
      <last_name>Philip Ginsburg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Innovative Medical Research of South Florida, 2999 NE 191 St., Suite 330</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel Babba</last_name>
      <phone>786-202-0998</phone>
      <email>gbmdresearch@live.com</email>
    </contact>
    <investigator>
      <last_name>Isaac Bassan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research of West Florida</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Hintz</last_name>
      <phone>727-466-0078</phone>
      <phone_ext>233</phone_ext>
      <email>chintz@crwf.com</email>
    </contact>
    <investigator>
      <last_name>Michael Weiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Borland-Groover Clinic PA, 4800 Belfort Road</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Benner</last_name>
      <phone>904-680-0871</phone>
      <email>sbenner@bgclinic.com</email>
    </contact>
    <investigator>
      <last_name>Mark Fleisher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunrise Medical Research, Inc. 4700 N. State Road Building A, Suite 111</name>
      <address>
        <city>Lauderdale Lakes</city>
        <state>Florida</state>
        <zip>33319</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia P. Ceballos</last_name>
      <phone>954-915-9991</phone>
      <email>research@sunrisemedicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Schneider, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research Center, 1690 Dunlawton Ave., Suite 110</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia Afghani</last_name>
      <phone>386-767-8800</phone>
      <email>nafghani@amrcus.com</email>
    </contact>
    <investigator>
      <last_name>Ammar Hemaidan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shafran Gastroenterology Center, 701 West Morse Blvd</name>
      <address>
        <city>WinterPark</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kara Fitch</last_name>
      <phone>407-629-8121</phone>
      <email>kara.fitch@gmail.com</email>
    </contact>
    <investigator>
      <last_name>. Ira Shafran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Agile Clinical Research Trials, 10945 State Bridge Road, Suite 401-403</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shelby Russell</last_name>
      <phone>470-328-1746</phone>
      <email>shelby@agilecrt.com</email>
    </contact>
    <investigator>
      <last_name>Alan Fixelle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlanta Gastroenterology Associates 550 Peachtree St. NE Suite 1600</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Johnson, RN, CCRC</last_name>
      <phone>770-612-8165</phone>
      <phone_ext>8613</phone_ext>
      <email>julie.johnson@atlantagastro.com</email>
    </contact>
    <investigator>
      <last_name>Michael Levine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Specialists of Georgia PC, 711 Canton Rd. Suite 300</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Maffei</last_name>
      <phone>678-819-4237</phone>
      <email>cmaffei@gigeorgia.com</email>
    </contact>
    <investigator>
      <last_name>Aasim Sheikh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago 5841 S. Maryland Ave, MC 4076, Room M404</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristi Milam</last_name>
      <phone>773-834-7414</phone>
      <email>kmilam@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Russell D Cohen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Iowa Digestive Disease Center, 2024 NW 92nd Court, #8</name>
      <address>
        <city>Clive</city>
        <state>Iowa</state>
        <zip>50325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jene Formard</last_name>
      <phone>515-225-6050</phone>
      <email>jenef@hmrtrials.com</email>
    </contact>
    <investigator>
      <last_name>Bernard Lehman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cotton-O'Neil Clinical Research Center, 720 SW Lane St.</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Hirst</last_name>
      <phone>785-270-4881</phone>
      <email>hhirst@stormontvail.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Welton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Delta Research Partners, 608 Grammont Street</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa McCullars</last_name>
      <phone>318-807-0819</phone>
      <email>drbhandari@suddenlinkmail.com</email>
    </contact>
    <investigator>
      <last_name>Raj Bhandari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Investigative Clinical Research, 612 Ridgely Avenue, Suite 401,</name>
      <address>
        <city>Annapolis</city>
        <state>Maryland</state>
        <zip>21401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Doremus</last_name>
      <phone>410-224-4887</phone>
      <email>robin@icrmd.com</email>
    </contact>
    <investigator>
      <last_name>Michael Epstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center For Digestive Health</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vijay Baraji</last_name>
      <phone>734-395-9146</phone>
      <email>vbaraji@troygastro.com</email>
    </contact>
    <investigator>
      <last_name>Sante Bologna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center For Digestive and Liver Disease, 714 Medical Parks Drive</name>
      <address>
        <city>Mexico</city>
        <state>Missouri</state>
        <zip>65265</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Burkemper</last_name>
      <phone>573-581-7196</phone>
      <email>Matt.Burkemper@gutdoc.us</email>
    </contact>
    <investigator>
      <last_name>Glenn Gordon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Billings Clinic, Research Center, 1045 No. 30th St.</name>
      <address>
        <city>Billings</city>
        <state>Montana</state>
        <zip>59101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Dignen</last_name>
      <phone>406-435-8490</phone>
      <email>Kdignen@billingclinic.org</email>
    </contact>
    <investigator>
      <last_name>Steven Hammond, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AGA Clinical Research Associates, Inc., 3205 Fire Road</name>
      <address>
        <city>Egg Harbor Township</city>
        <state>New Jersey</state>
        <zip>08324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Stevens</last_name>
      <phone>609-407-1220</phone>
      <email>theresa@atlanticgastro.com</email>
    </contact>
    <investigator>
      <last_name>Barry Kaufman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NY Scientific, 1517 Voorhies Ave, Ground FL</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shahid Mahmood</last_name>
      <phone>347-547-6972</phone>
      <email>smahmood@nyscientific.net</email>
    </contact>
    <investigator>
      <last_name>Igor Grosman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PMG Research of Winstom-Salem, LLC, 1901 S. Hawthorne Rd. Suite 306</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Savannah Boyd</last_name>
      <phone>336-768-8062</phone>
      <email>sboyd@pmg-research.com</email>
    </contact>
    <investigator>
      <last_name>Brian Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio GI and Liver Institute, 2925 Vernon Place 100</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gayle Combs</last_name>
      <phone>513-872-4549</phone>
      <email>gcombs@ccrstudy.com</email>
    </contact>
    <investigator>
      <last_name>Alan Safdi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio GI and Liver Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Snow</last_name>
      <phone>513-587-0410</phone>
      <email>asnow@ccrstudy.com</email>
    </contact>
    <investigator>
      <last_name>Christopher South, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Great Lakes Gastroenterology Research, LLC, 9485 Mentor Avenue, Suite 105</name>
      <address>
        <city>Mentor</city>
        <state>Ohio</state>
        <zip>44060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Shelby, RN</last_name>
      <phone>440-205-1225</phone>
      <phone_ext>212</phone_ext>
      <email>glg.lori@outlook.com</email>
    </contact>
    <investigator>
      <last_name>Keith Friedenberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center, 4800 Almeda Avenue</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sean Connery</last_name>
      <phone>915-215-5175</phone>
      <email>sean.connery@ttuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Richard McCallum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine, 7200 Cambridge Street Suite 180.184, 10th Floor</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermina Cruz</last_name>
      <phone>713-798-7616</phone>
      <email>gcruz@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Hou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spring Gastroenterology Associates, 8901 FM 1960 West</name>
      <address>
        <city>Humble</city>
        <state>Texas</state>
        <zip>77036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aijaz Hussain</last_name>
      <phone>281-822-1555</phone>
      <email>ahussain@springclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Ravi Moparty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital and Clinics, H6/517 CSC-MC5124, 600 Highland Ave.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Richie</last_name>
      <phone>608-262-5404</phone>
      <email>kr2@medicine.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Reichelderfer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Discovery Clinical Services Ltd. 601 A Discovery St.</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T 5G4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Warke</last_name>
      <phone>250-386-0023</phone>
      <email>lwarke@dresearch.ca</email>
    </contact>
    <investigator>
      <last_name>Denis Petrunia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sourasky Medical Center, 6 Weizman Street</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Liana Shamayev</last_name>
      <phone>+972 3 697-3011</phone>
      <email>lianash@tlvmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Sigal Fishman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Canada</country>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://www.redhillbio.com</url>
  </link>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>June 2, 2014</lastchanged_date>
  <firstreceived_date>September 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crohn's Disease</keyword>
  <keyword>moderate to severe</keyword>
  <keyword>remission</keyword>
  <keyword>MAP</keyword>
  <keyword>antibiotic</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Crohn Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
